Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics Inc. is positioned for significant financial growth, with projected risk-adjusted revenues from key indications expected to rise dramatically, reaching approximately $698 million by 2030 for hypercortisolism and nearly $824 million for Cushing's syndrome-related relacorilant. The company has seen record levels of prescribers and patients for its existing treatment, Korlym, driven by heightened physician awareness, which suggests a robust market for its therapies. Additionally, the anticipated approval of relacorilant could lead to further revenue increases, particularly if adopted in challenging patient populations such as those with resistant hypertension and difficult-to-control diabetes, potentially adding an estimated $400 million to $500 million annually.

Corcept Therapeutics Inc. faces significant operational challenges, which may lead to lower revenue in the first quarter of 2025 compared to the rest of the year, thereby impacting its financial performance. A survey indicated that physician awareness and understanding of the drug Korlym remain low, with 70% of prescribing doctors citing limited awareness and data as key barriers to adoption, alongside concerns regarding drug cost and safety. The discrepancy between the actual prevalence of hypercortisolism as reported in clinical findings and the belief of endocrinologists could hinder potential market growth and limit revenue opportunities for Corcept in the foreseeable future.